Biopharma Dealmaking in 2023. Perspective and Projections
Deal flow decreased, average deal values dropped, and headline grabbing M&As slowed to a trickle. Inflation soared, IPOs cratered, and SPAC just might be the new four-letter-word. After a year where the global economy slowed and uncertainty reigned, what does 2023 hold for the biopharma industry?
Chris Dokomajilar, Founder and CEO at Dealforma, returns to Inova to offer his third annual review of the year in life science partnering. He’ll unlock all the trends in the dealmaking data and draw on his deep industry expertise to project what we’re likely to see in the biopharma dealmaking in 2023.
Watch the replay to learn:
- Why large pharma merger activity slowed
- Where VC investments flowed, and why
- How and where pre-clinical biotechs raised capital
- Whether licensing upfronts will bounce back in the new year
Please complete the form below
All fields marked with a * are required.
personal data by Inova as detailed in the Privacy Statement.